Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs Schlumberger NV (SLB) Price & Performance

Novo Nordisk A/STrade
Schlumberger NVTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Schlumberger NV — how do they compare? Novo Nordisk A/S trades at $46.02 (market cap $207.85B), while Schlumberger NV trades at $53.7 (market cap $79.67B). The key difference: Novo Nordisk A/S is far larger — about 2.6× Schlumberger NV's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.

NVOSLB
Market Cap
$207.85B$79.67B
Sector
HealthEnergy
52-Week High
$63.98$58.01
52-Week Low
$35.29$31.72
Enterprise Value
$222.55B$88.40B
Dividend Yield
3.81%2.2%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO

About Schlumberger NV

Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.

Read more on SLB